Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a $4 statin be the migraine cure We've been missing?

NCT ID NCT06248671

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests whether atorvastatin, a common cholesterol medicine, can prevent migraine attacks in adults with episodic migraine (4-14 attacks per month). Researchers will compare a 20mg dose, a 40mg dose, and a placebo over several months. The goal is to see if the drug reduces the number of migraine days and is safe, building on promising results from smaller studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65 years. * Signed informed consent. * Episodic migraine with or without aura according to ICHD-3 criteria. * At inclusion, patients should retrospectively have from 4 to 14 migraine attacks per month during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment. * Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history. * Start of migraine before 50 years. * No use of other migraine prophylactics during the study. * For women of child-bearing potential, there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception. After the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer attacks than 4 or more than 14 per month, the baseline period can be extended to 8 weeks, and the patient can be randomized to a treatment then if there is a mean of 4-14 attacks per 4 weeks during the 8-week's period. Exclusion Criteria: * Interval headache not distinguishable from migraine. * Chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days/month. * Pregnancy, planning to get pregnant, inability to use contraceptives, and lactating. * Clinical information on or signs of cholestasis or decreased hepatic or renal function. * High degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator. * Hypersensitivity to statins or previous use of statins. * History of angioneurotic oedema. * Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study. * Current use of antiviral treatment against hepatitis C. * Significant psychiatric illness. * Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years. * Requiring detoxification from acute medication (triptans, opioids). * Consistently failing to respond to any acute migraine medication. * Alcohol or illicit drug dependence. * Inability to understand study procedures and to comply with them for the entire length of the study. * Treatment for hypothyroidism. * Lactose intolerance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Episodic migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Haukeland University Hospital

    RECRUITING

    Bergen, Norway

  • Oslo University Hospital, Rikshospitalet

    NOT_YET_RECRUITING

    Oslo, Norway

  • Oslo University Hospital, Ullevål

    NOT_YET_RECRUITING

    Oslo, Norway

  • St. Olavs hospital

    RECRUITING

    Trondheim, 7022, Norway

  • University Hospital Northern Norway

    RECRUITING

    Tromsø, Norway

  • University Hospital, Akershus

    NOT_YET_RECRUITING

    Lørenskog, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.